ReviewJournal of neuro-oncology1999
Primary central nervous system lymphoma: from clinical presentation to diagnosis.
Review in Journal of neuro-oncology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Article
- A Case of Primary Central Nervous System Lymphoma Located at Brain Stem in a Child.Brain tumor research and treatment · 2016Article
- Squash cytology of primary central nervous system lymphoma in an immunocompetent patient.Asian journal of neurosurgery · 2013Article
- Primary central nervous system lymphoma.Current treatment options in oncology · 2013Article
- A 60-year-old Indian male with altered sensorium and extensive lymphoma of the scalp.Seminars in oncology · 2013Article
- Treatment outcomes and survival in patients with primary central nervous system lymphomas treated between 1995 and 2010 - a single centre report.Radiology and oncology · 2012Article
- High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma.Journal of neuro-oncology · 2011Review
- Primary CNS lymphoma presenting as fever of unknown origin.Journal of neuro-oncology · 2009Article
- Immunophenotyping of Tumours.Medical journal, Armed Forces India · 2008Article
- Diagnosis and treatment of primary central nervous system lymphoma.Current oncology reports · 2005Review
- Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2004Review
- Primary central nervous system lymphoma.Current oncology reports · 2004Review
- [Primary intraocular lymphoma].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2004Review
- Primary Central Nervous System Lymphoma.Current treatment options in neurology · 2003Article
- Molecular pathology of primary intraocular lymphoma.Transactions of the American Ophthalmological Society · 2003Article
- MRI findings of primary CNS lymphoma in 26 immunocompetent patients.Korean journal of radiologyArticle
- Intraocular lymphoma: update on diagnosis and management.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunocompetent patients with primary central nervous system lymphoma (PCNSL) present with a median age of 55 years, immunosuppressed patients with a median age of 40 years. They show a broad range of signs and symptoms. Symptoms of increased intracranial pressure and personality change are most frequent, followed in frequency by ataxia and hemiparesis. The median time from onset of symptoms to diagnosis is 3-5 months in immunocompetent patients and 2 months in immunodeficient patients. The time to diagnosis can be considerably longer in patients with slowly developing personality change or fluctuating symptoms due to spontaneous or steroid-induced remission of so-called sentinel lesions. Native CT scans show iso- or hyperdense lesions with homogenous contrast enhancement. T1-weighted MRI scans show hypointense and T2-weighted scans hyperintense lesions. The definitive diagnosis of PCNSL requires biopsy. In some cases, however, the definitive diagnosis may exclusively be made by the demonstration of malignant B-lymphocytes in the cerebrospinal fluid.
Indexed as
Identifiers
10563426What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.